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Abstract: Cichorium intybus L. or chicory plants are a natural source of health-promoting compounds
in the form of supplements such as inulin, as well as other bioactive compounds such as sesquiterpene
lactones (SLs). After inulin extraction, chicory roots are considered waste, with most SLs not being
harnessed. We developed and optimized a new strategy for SL extraction that can contribute to
the conversion of chicory root waste into valuable products to be used in human health-promoting
applications. In our work, rich fractions of SLs were recovered from chicory roots using supercritical
CO2. A response surface methodology was used to optimize the process parameters (pressure,
temperature, flow rate, and co-solvent percentage) for the extraction performance. The best operating
conditions were achieved at 350 bar, 40 ◦C, and 10% EtOH as a co-solvent in a 15 g/min flow
rate for 120 min. The extraction with supercritical CO2 revealed to be more selective for the SLs
than the conventional solid–liquid extraction with ethyl acetate. In our work, 1.68% mass and a
0.09% sesquiterpenes yield extraction were obtained, including the recovery of two sesquiterpene
lactones (8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin), which, to the best of our knowledge,
are not commercially available. A mixture of the abovementioned compounds were tested at
different concentrations for their toxic profile and anti-inflammatory potential towards a human
calcineurin/NFAT orthologue pathway in a yeast model, the calcineurin/Crz1 pathway. The SFE
extract obtained, rich in SLs, yielded results of inhibition of 61.74 ± 6.87% with 50 µg/mL, and
the purified fraction containing 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin inhibited the
activation of the reporter gene up to 53.38 ± 3.9% at 10 µg/mL. The potential activity of the purified
fraction was also validated by the ability to inhibit Crz1 nuclear translocation and accumulation.
These results reveal a possible exploitable green technology to recover potential anti-inflammatory
compounds from chicory roots waste after inulin extraction.
Keywords: supercritical CO2 extraction; sesquiterpene lactones; anti-inflammatory potential
1. Introduction
At present, there is a growing interest in the potential benefits of nutritional com-
pounds for disease prevention, which in turn also means an increasing demand for natural
and nutritional food [1]. Biologically active compounds and functional ingredients (vi-
tamins, antimicrobials, antioxidants, colorants, etc.) from natural sources are of great
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commercial interest, especially in the form of dietary supplements. The taproot of chicory
(Cichorium intybus L., Asteraceae family) contains several health-related compounds such
as inulin, flavonoids, vitamins, and sesquiterpene lactones (SLs) [2–4]. Chicory leaves have
been consumed in Europe for many centuries, and the roots are currently used for the
production of inulin, a fructose-based polymer that is added to numerous food products
as a dietary fiber and sweetener [5]. After inulin extraction, the remaining biomass is
considered waste, even though the roots are rich in other health-promoting compounds
such as SLs. Several bioactivities have been previously associated with SLs, for instance,
those that are antimicrobial, anti-inflammatory, and antiparasitic [3,5–12]. The most rel-
evant SLs previously identified in chicory roots [13–15] include lactucin, lactucopicrin,
11β-13-dihydrolactucin, 11β-13-dihydrolactucopicrin, and 8-deoxylactucin [16].
SL extraction from several Asteraceae species has been carried out using different
organic solvents or mixtures such as methanol, ethyl acetate, chloroform, n-hexane, and
ethanol (EtOH) [17–22]. The need to minimize toxic solvent utilization has motivated the
development of new environment-friendly processing technologies that can be carried out
at the industrial scale. In this field, high pressure technologies are revealed to be remarkably
efficient in enabling a more selective and effective recovery of high-value compounds
from natural sources [23–25]. One such technology, supercritical fluid extraction (SFE),
is generally performed using carbon dioxide (CO2). CO2 has a moderately low critical
pressure and temperature (74 bar, 32 ◦C) and is nontoxic; it is available in high purity
at relatively low costs and can be easily removed from the extract [26–28]. Supercritical
CO2 is an excellent solvent for the extraction of nonpolar and low molecular weight
compounds [25,29]. Solvent extraction power and selectivity have been widely studied and
depend especially on SFE operating conditions, which includes the possibility of adding
a co-solvent (usually water or EtOH) to modify supercritical CO2 polarity, enhancing
target molecules solubility [23,25,26]. The combination of CO2 properties turns SFE into a
sustainable and safe extraction technique for the extractions of ingredients for supplements
and health care products [24,26,27].
The purpose of this study is to contribute to the valorization of chicory root by
developing for the first time a high-pressure strategy to extract SLs for human health-
promoting applications. Chicorium intybus L. SFE extract is highly rich in different SLs
such as lactucin, lactucopicrin, 11β-13-dihydrolactucin, 11β-13-dihydrolactucopicrin, 8-
deoxylactucin, and 11β,13-dihydro-8-deoxylactucin. After a chromatographic process,
a purified fraction of a mixture of 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin
could be isolated. The SFE extract and the purified fraction are tested in vitro for its
toxicity at different concentrations as well its anti-inflammatory potential. In our study,
the SFE extract was able to inhibit 61.74 ± 6.87% of the transcription factor activity with a
concentration of 50 µg/mL an inhibition rate in the same range of those observed for the
immunosuppressant pharmaceutical drug FK506 also known as tacrolimus. Furthermore,
the purified fraction was also tested for the potential anti-inflammatory capacity, revealing
a capacity to inhibit Crz1 activation by 53.38 ± 3.9% at 10 µg/mL.
2. Results and Discussion
2.1. Supercritical CO2 Extraction of SLs
Freeze-dried and milled (particle size < 1 mm) Cichorium intybus L. roots were sub-
jected to SFE. Based on the preliminary extractions (data not shown) with supercritical
CO2 as a solvent, the procedure resulted in a low mass yield extraction (0.25 mg extract/g
raw material) while the mass yield increased when an organic co-solvent (10% EtOH) was
used (10 mg extract/g raw material). An extraction kinetic was made (data not shown) at
300 bar and at 50 ◦C with a flow rate of 10 g/min, including 10% EtOH as a co-solvent, and
120 min was considered the best extraction time for the SFE processing of chicory roots.
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A design of experiments (DOE) was planned in order to optimize the extraction proce-
dure and to study the effect of process variables on the mass yield and SL concentration
in the extract. SFE extracts were characterized by HPLC-DAD and were based on the
SLs that are most abundant in chicory roots [8,14,18,30]. Four different compounds were
identified by comparing the retention times of the commercially available SL standards:
11β,13-dihydrolactucin, lactucin, 11β,13-dihydrolactucopicrin, and lactucopicrin. The SL
concentration in the extract was calculated based on the sum of the abovementioned SLs
(Figure 1). In a first approach flow rate (10 g/min), the extraction time (120 min), and the
co-solvent percentage (10% EtOH) were kept constant to evaluate the effect of temperature
(40–80 ◦C) and pressure (100–550 bar) (see Table 1, DOE 1, two factors with three level
face-centered composite design).
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Figure 1. Major sesquiterpene lactones identified in Cichorium intybus L. root extracts.
Table 1. Variables used in the two different design of experiments (DOE) and actual values of
variables for the coded values. First process optimization (DOE 1) with 2 process variables, i.e.,
temperature and pressure, and after the final process parameters optimization (DOE 2) with 3 process
variables, i.e., flow rate, co-solvent percentage, and temperature.
Levels
Variable, unit −1 0 1
DOE 1
Temperature, ◦C 40 60 80
Pressure, bar 100 325 550
DOE 2
Temperature, ◦C 25 33 40
Co-solvent, % EtOH 10 25
Flow rate, g/min 10 20 30
The obtained results regarding mass and SL concentration in the extract are shown in
Figure 2. The regression analysis of the data shows that for a 90% confidence level (p < 0.10),
the SL concentration in the extract was negatively affected by extraction temperature
(p = 0.060). While the effect of CO2 pressure was not significant for the SL concentration,
this parameter ha a significantly quadratic effect on mass yield (p = 0.040), which means
that the optimal levels of pressure are found in the middle of the experimental range.
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(values linked to right axis) represent extraction mas yield and coloured bars (values linked to left axis) represent the
concentration of the major SLs extracted from Cichorium intybus L. roots from supercritical CO2 extraction process.
As graphically described in Figure 2, the maxi um mass yield was obt ined (5.73 mg/g
raw material) when the co ditions epicte in assay 9 were applied (80 ◦C, 325 bar, and a
continuous flow rate f 10 g/min CO2 with 10% of EtOH as the co-solvent), corroborating
with the predict d sul s by the model. On the other hand, the minimum yield was
achieved when the xtraction was conducted at lower pressu es (100 bar) as represented in
assays 1, 4, nd 8, with the lowest valu (0.43 mg/g raw material) chieved at high t mper-
atures (assay 8). Regarding the SL conce tration in the extract, the effect of the temperature
is visible when comparing extraction assays 1, 4, and 8. At the same pressure (100 bar), the
SFE performed at a lower temperature (40 ◦C) resulted in an extraction four times higher in
SLs (42.7; 8.2 and 11.6 µg/mg extract, respectively) compared to the ones performed at high
temperature (80 ◦C). The most selective extraction is represented in assay 1 (42.7 µg/mg
extract) and the lowest in assay 4 (8.2 µg/mg extract). Since no optimal extraction point
was obtained with DOE 1, a second DOE (Table 1, DOE 2) was created to narrow the
optimal extraction region based on previously obtained results with a fixed temperature
at 40 ◦C and pressure at 350 bar. A set of experiments, including three center points, was
carried out to optimize new variables, namely the co-solvent percentage (10–40% EtOH),
flow rate (10–30 g/min), and low temperature (25–40 ◦C) in the extraction process.
Figure 3 shows mass and SL concentration in the extract obtained in DOE 2. They were
used to estimate the linear and quadratic effects of the variables and their synergies. The
response surfaces (Figure 3) fitted to the SL concentration in the extract can be described
by second-order polynomial models as a function of co-solvent percentage, temperature,
and flow rate (Table 2). In these response surface models, for a 95% confidence level,
the significant effects of p < 0.05 were included in the model equations. The high values
for both R2 and Radj2 of these models (Table 2) suggest a close agreement between the
experimental data and the theoretical values predicted by the model.
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Table 2. Model equations for the response surfaces, after final SFE optimization (DOE 2), fitted to the values of mass yield
(MY) and the four major SLs extracted as a function of temperature (A), co-solvent percentage (B), and flow rate (C), and
their respective R2 and Radj2.
Polynomial Model Equations R2 Radj2
MY = 1.232 + 0.936A + 0.403B − 0.124A2 + 0.285BC 0.99 0.98
11β,13-dihydrolactucin = 4.2 + 0.748A − 6.096B − 1.519C + 4.01B2 0.98 0.97
Lactucin = 6.262 + 1.046A − 9.261B − 2.155C + 6.088B2 0.98 0.98
11β,13-dihydrolactucopicrin = 1.688 − 0.876B 0.90 0.87
Lactucopicrin = 5.564 − 4.293B − 1.271C + 1.236B2 0.96 0.94
The analysis of the second response surface model for SL extraction (Figure 4) shows
that there is a positive effect of temperature and a negative effect of co-solvent percentage
and flow rate in the SL concentration in the extract.
As already observed in the previous design of experiments, temperature is the most
important parameter for the selectivity of the process. By varyi g the temperature again, it
was ssible to obtain the valu that best favors the extraction of the SLs from Cichorium
intybu L. roots. This positive eff ct means that the increase i temperature favors the
extraction up to 40 ◦C, and beyond this v lue, this parameter has a negative effect in the
process. As shown in Figure 4, the best temperature to extract all the four SLs is 40 ◦C.
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extract mass does not mean an increase in SL content, as shown in Figure 3. As it can be 
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Figure 4. Response surfaces (DOE 2) fitted to the SL concentration in the extract as a function of temperature, co-solvent
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depending on the conditions of the three axes. In blue, the minimum extraction; in red, the maximum extraction achieved for
each SL. To maximize SL extraction, the best SFE is conducted at high temperature (40 ◦C) with a low flow rate (10 g/min)
and low co-solvent percentage (10% EtOH).
When comparing all extraction attempts (Figure 3), we can see that the best selectivity
results are obtained with low co-solvent percentages (assays 1, 2, 6, 13, and 14). Therefore,
the best selectivity result was obtained when the extraction was conducted at 40 ◦C with
a low flow rate (10 g/min) and low co-solvent percentage (10% EtOH). This extraction is
characterized by presenting a 5.91% SL content on the final extract, and it is represented in
assay 13 (Figure 3).
In contrast, the mass yield was higher when the extraction process was performed at a
high flow rate (30 g/min) with high co-solvent percentages (40% EtOH) (assays 5, 12, and
17; Figure 3). This result was expected because a reduced selective extraction is obtained
when high flow rates and co-solvents are applied in SFE. However, an increase in extract
mass does not mean an increase in SL content, as shown in Figure 3. As it can be noted,
when the polarity of the extractant solvent is changed, the final mass characterization
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can also be altered. Moreover, as the solvent (CO2 + EtOH) flow rate was increased,
independently from the temperature applied, the extraction capacity of the described
system increased (red area, Figure 5). Here, the best conditions to increase the mass yield
were 40 ◦C, 30 g/min flow rate with 40% EtOH as the co-solvent, resulting in a 260 mg/g
raw material with 0.91% of SLs in its composition (assay 17; Figure 3).
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An optimal condition to maximize both responses (mas yield and SL yield) was
not obtained, but a regio where all criteria were met was found at 350 bar, 40 ◦C with a
conti uous flow rate of 13–19 g/min flow with 10% EtOH as a co-solvent; this regio is
co monly called the sweet spot.
From the sweet spot, the best operating conditions were set, corresponding to a
120 min, at 350 bar, 40 ◦C, and 15 g/min flow with 10% EtOH as the co-solvent. This
optimization resulted in a 16.8 mg/g raw material extraction with 53 µg/mg extract of
SLs in its composition, accounting for an acceptable balance between mass yield and SL
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through the modulation of Crz1, the yeast orthologue of the human nuclear factor of
activated T-cells (NFAT) pathway, was also evaluated for the nontoxic concentrations
of the SFE extract (Figure 8B). SFE demonstrated a higher anti-inflammatory potential at
concentrations such as 50 and 75 µg/mL, reducing the calcineurin/Crz1 pathway activation,
up to 61.74 ± 6.87% and 59.5 ± 0.04%, respectively, at rates statistically comparable to
the positive control FK506 (62.48 ± 2.10%) with a calculated IC50 of 38.81 ± 0.32 µg/mL
(Figure 8B). Both in human and in yeast, i.e., NFAT and Crz1, respectively, are under the
control of calcineurin. Human calcineurin and yeast calcineurin share a high evolutionary
similarity, making this model ideal for the screening of compounds with anti-inflammatory
potential. In the presence of a stimulus (MnCl2), Crz1 dephosphorylates from calcineurin
and migrates towards the nucleus, thus promoting the expression of calcineurin dependent
response element (CDRE) regulated genes similarly to human NFAT. SFE extract is rich
in SLs, which have been already demonstrated to possess anti-inflammatory potential
in a previous study [34]. However, this extract contains unexplored SLs such as the 8-
deoxylactucin and 11β,13-dihydro-8-deoxylactuin, whose anti-inflammatory activity was
not previously described towards the calcineurin/Crz1 pathway.
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2.5. Purified Fraction Anti-Inflammatory Potential
As mentioned above, other pure SLs present in the SFE extract, such as lactucin,
lactucopicrin, 11β,13-dihydrolactucin and 11β,13-dihydrolactucopicrin, all of which are
commercially available, were already investigated for their anti-inflammatory potential in
our previous study [34]. Therefore, we decided to explore the potential of this novel puri-
fied fraction containing a mixture of 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin.
In order to measure its associated toxicity, yeast cells were exposed to different concentra-
tions of SFE purified fraction. Here, 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin
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demonstrated no toxicity towards yeast cells at concentrations ranging from 12.5 µg/mL
to 100 µg/mL (Figure 9A).
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oiety as escribed to be the ost bioactive group resent in S s ith res ect to anti-
infla atory activity by interacting ith proteins that contain exposed sulfhydryl groups
via ichael-type addition [35]. This compound may be able to interact with calcineurin or
through its exposed sulfhydryl groups present in its catalytic subunit [36,37]. Although α-
methylene-γ-lactones rings are the most bioactive group, they may also present the ability
to create conjugates via Michael-type addition with glutathione intracellularly—a process
already described for other chicory SLs, lactucin and lactucopicrinand other SLs such as
noblin—that become unavailable for further reaction with the target proteins [38,39].
In a previous study, chicory SL 11β,13-dihydrolactucin, lacking the α-methylene-
γ-lactone ring, was able to modulate the activation of calcineurin/Crz1 pathway due
to the presence of α,β-unsaturated carbonyl groups [34]. In addition, 11β,13-dihydro-8-
deoxylactucin also does not contain the α-methylene-γ-lactones group, but it contains other
functional groups such as α,β-unsaturated carbonyl, similarly to 11β,13-dihydrolactucin,
possibly still being able to modulate the calcineurin/Crz1 pathway acting as a potential
anti-inflammatory compound [34].
To confirm the effect of purified fraction containing 8-deoxylactucin and its dihydro
variant on Crz1 activity, fluorescence microscopy was used as a means to assess their
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interference with Crz1 nuclear translocation and the accumulation of the transcription
factor Crz1 at the concentration of the previously calculated IC50 of the fraction (7.2 µg/mL).
The Crz1 signal is dispersed throughout the cells in the control condition, challenging cells
with MnCl2 triggered Crz1 nuclear accumulation (48.7%), which was inhibited by SFE
purified fraction treatment (14.6%) in a similar manner to that of the positive control FK506,
known to inhibit calcineurin activity and thereby preventing the translocation of Crz1 to
the nucleus (Figure 10).
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either with or without 7.2 µg/mL of purified fraction, challenged with 3 mM MnCl2, and Crz1–GFP
subcellular distribution was monitored using fluorescence microscopy. The immunosuppressant
FK506 was used as positive control. Approximately 1800 cells representing each conditi n were
counted. Rep sentative imagens are shown, nd the value are the mean of percentage of nuclear
Crz1–GFP ± SD of three biological replicates. Statistical differences are denoted as *** p < 0.001
relative to activated cells.
3. Materials and Methods
3.1. Chemicals
CO2 pure grade (99.95%, Air Liquide, Lisbon, Portugal) and EtOH (96%) were used
for high pressure extraction experiments. Solvents used for conventional extractions purifi-
cation steps and chromatographic analysis included ethyl acetate (99.98%, Fisher scientific
U.K. Limited, Loughborough, UK), methanol (99.8%, Fisher scientific U.K. Limited, Lough-
borough, UK), dichloromethane (Honeywell Riedel-de Haën, Germany), distilled water,
and ultrapure water purified with a Milli-Q water purification system (Merck Millipore,
Billerica, MA, USA). For the inflammation assays, the inflammatory stimulus was carried
out by the usage of MnCl2 (Merck, Darmstadt, Germany), and the anti-inflammatory posi-
tive control was carried by FK506 (Cayman Chemicals, Ann Arbor, MI, USA). Cellular lysis
was preformed using Yeast Protein Extraction Reagent (Y-PER; ThermoFisher Scientific, Sci-
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entific, Rockford, IL, USA). To quantify the expression of reporter gene lacZ, we employed
a solution buffer composed of Na2HPO4 (ROTH, Karlsruhe, Germany), NaH2PO4·H2O
(Merck, Buchs, Switzerland), KCl (Panreac, Barcelona, Spain), and MgSO4·7H2O (Merck,
Buchs, Switzerland), containing o-nitrophenyl β-D-galactopyranoside (ONPG; Sigma–
Aldrich®–Poole, Dorset, UK). Nuclear staining was carried out using nuclear dye Hoechst
33342 (Sigma, Buchs, Switzerland).
3.2. Raw Material
Chicory roots were obtained from a processing industry (Sensus, The Netherlands),
which were harvested in November 2018. For sample preparation, roots were received,
cleaned, and cut into pieces (1 cm) for freeze-drying (Coolsafe Superior Touch 55-80,
Scanvac). The samples were further milled, and the particle size was determined using an
AS 200 basic vertical vibratory sieve shaker (Retsch, Haan, Germany), with a measuring
range between 250 and 1000 µm. The milled roots were stored and protected from light
while kept at room temperature in a desiccator until the day of the experiments.
3.3. Extraction and Fractionation Procedures
3.3.1. Supercritical CO2 Extractions
High-pressure extractions were carried out in an SFE system (Thar Technology,
Pittsburgh, PA, USA, model SFE-500F-2-C50) [40]. Liquid CO2 was fed into the extraction
vessel using a Thar SFC P-50 high pressure pump (Thar Technology, Pittsburgh, PA, USA).
The extraction vessel was filled with 10 g of freeze-dried, milled chicory roots and glass
beads in order to decrease solvent consumption. EtOH used as a co-solvent was pumped
to the extraction vessel using a Thar SFC P-50 high pressure pump (Thar Technology,
Pittsburgh, PA, USA). The vessel was pressurized with CO2 until reaching the required
pressure (100–550 bar), which was maintained by an automated back pressure regulator
(Thar SFC ABPR, Thar Technology, Pittsburgh, PA, USA). CO2 was expanded into the first
fraction collector, and the extracts were recovered in a flask placed in an ice bath.
3.3.2. Experimental Design Analysis/Statistical Analysis
Response surface methodology, a collection of statistical and mathematical techniques
for improvement and optimize processes, is proposed to model the effect of different
parameters such as pressure, temperature, co-solvent percentage, and flow rate on the
extraction performance by SFE [41–43].
In this study, response surface methodology was used to model the recovery of SLs
from chicory roots and to optimize the SFE process conditions. The extraction of SL was
carried out following two different central composite face-centered (CCFC) designs as a
function of pressure (100–550 bar), temperature (25–80 ◦C), flow rate (10–30 g/min), and
co-solvent percentage (10–40%) to optimize the mass and SL extraction yield. After the
selection of independent variables and their ranges, experiments were established based
on a CCFC design, and each one was coded at three levels, i.e., −1, 0, and +1 (Table 1). The
results of the CCFC, particularly the total mass and the SL concentration in the extract value,
were analyzed using the software MODDE (MODDE Go 12.1 32-bit, Umetrics, Sweden).
Both linear and quadratic effects of each factor under study, as well as their interactions,
were calculated based on different extractions that were performed in a random order, as
defined by the software. A surface, as described by a second-order polynomial equation,
was fitted to each set of experimental data points. First- and second-order coefficients of
the polynomial equations were generated by regression analysis. The fit of the models was
evaluated using the determination coefficients (R2) and adjusted R2 (Radj2).
3.3.3. Conventional Solid–Liquid Extraction
The solid–liquid extraction, a process implemented by an industrial project partner
(Sensus, The Netherlands), was performed for comparison with the SFE results. Briefly, the
freeze-dried and milled Cichorium intybus L. roots were extracted with either ethyl acetate
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or water (raw material:solvent 1:10 (w/v)) for 1 h at 60 ◦C with mechanic stirring (RW20.n
IKA, Labortechnik, Germany) at 900 rpm. Then, the extract was filtered (qualitative filter
paper, 125 mm, from Filter-Lab) and centrifuged (Eppendorf Centrifuge 5810 R) to remove
any remaining solid part of the unsolved raw material. The extract was dried in a rotary
evaporator under reduced pressure at 40 ◦C. The experiments were performed in triplicate.
3.3.4. Flash Column Chromatography Purification
Purification of the crude extract obtained from SFE consisted of dry loading approx-
imately 1.5 g of the sample into a chromatographic column (30 × 400 mm) packed with
silica gel 60 (0.04–0.06 mm, 230–400 mesh ASTM). The eluent for the purification was
dichloromethane:methanol (9.5:0.5), which was used with an isocratic flow. Thin-layer
chromatography (TLC) was conducted with TLC silica gel 60 F 254 and visualized under
UV light to follow the purification, using the same eluent system. The pure fractions were
collected, and the solvent was evaporated in a rotary evaporator under reduced pressure
at 40 ◦C, for further analysis.
3.4. SL Analysis
3.4.1. Quantification of SL by HPLC with Diode-Array Detector (HPLC-DAD)
HPLC analyses were carried out on a Thermo HPLC Dionex Ultimate 3000, equipped
with a quaternary pump, solvent degasser, autosampler, and column oven, coupled to a
Photodiode Array Detector Thermo Dionex DAD-3000. The separation was performed on
a reversed-phase column (LiCrospher® 100 RP-18, 250 × 4 mm; 5 mm; Merck®) at 35 ◦C.
Elution was carried out in gradient mode employing the following solvent system: mobile
phase A, methanol/water 14/86 (v/v); mobile phase B, methanol/water 64/36 (v/v). The
gradient program used was 0 to 20 min, 100–58% A; 20 to 30 min, 58% A; 30 to 45 min,
58–0% A; 45 to 50 min, 0% A; 50 to 52 min, 0–100% A; 52 to 62 min, 100% A. The flow rate
used was 0.5 mL/min, and the injection volume was 20 µL. A photodiode array detector
was used to scan the wavelength absorption from 210 to 600 nm. The software used was
Thermo Scientific™ Dionex™ Chromeleon™ (version 7.2 SR4) processed data.
3.4.2. Identification of SL by Liquid Chromatography–Mass Spectrometry (LC-MS)
For LC-MS analysis purified fraction 1 was dissolved in 70% methanol containing
formic acid (0.1%) at the concentration of 10 µg/mL. LC-MS analysis was performed using
the LC-PDA-LTQ-Orbitrap FTMS system (Thermo Scientific), which consists of an Acquity
UPLC (H-Class) with Acquity eLambda photodiode array detector (220–600 nm) connected
to a LTQ/Orbitrap XL hybrid mass spectrometer equipped with an electrospray ionizator
(ESI). The injection volume was 5 µL. Chromatographic separation was conducted on
a reversed phase column Luna C18 column (2.0× 150 mm, 3 µm; Phenomenex, USA)
at 40 ◦C. Degassed eluent A (ultra-pure water: formic acid (1000:1, v/v)) and eluent B
(acetonitrile:formic acid (1000:1, v/v)) were used at a flow rate of 0.19 mL min−1. A linear
gradient from 5 to 75% acetonitrile (v/v) in 45 min was applied, which was followed by
15 min of washing and equilibration. FTMS full scans (m/z 90.00–1350.00) were recorded
with a resolution of 60,000.
3.5. Anti-Inflammatory Evaluation
3.5.1. Saccharomyces Cerevisiae Strains and Growth Conditions
The S. cerevisiae strains used in this study were YAA3 (his3::CRZ1-GFP-HIS3) and
YAA5 (aur1::AUR1-C-4xCDRE-lacZ) [39]. The growth conditions were similar to those
previously described [34]. Briefly, a preinoculum was prepared in an SC (synthetic com-
plete) medium (0.79% (w/v) CSM (MP Biomedicals, Inc.—Fisher Scientific, Irvine, CA,
USA), 0.67% (w/v) YNB (DifcoTM Thermo Scientific Inc., Waltham, MA, USA), and 2%
(w/v) glucose), and cultures were incubated overnight at 30 ◦C under orbital shaking.
Cultures were diluted in a fresh medium and incubated under the same conditions until
the optical density at 600 nm (OD600) reached 0.5 ± 0.05. Readings were performed in a
Molecules 2021, 26, 2583 14 of 17
96-well microtiter plate using a Biotek Power Wave XS plate spectrophotometer (Biotek®
Instruments, Winooski, VT, USA).
3.5.2. Cell Viability Assays
Cell viability was monitored as previously described [34]. Briefly, 100 µL of cultures
diluted to a final OD600 = 0.025 ± 0.0025 were placed into 96-well microplates; 10 µL of cell
titer blue reagent (Promega, WI, USA) were added, and the plates were incubated for 3 h
at 30 ◦C. Fluorescence was measured in 30 min intervals at emission wavelength 580 nm
using the Biotek Power Wave XS Microplate Spectrophotometer (Biotek® Instruments,
Winooski, VT, USA). Doses of chicory SFE extracts ranging from 100 to 1000 µg/mL, and
purified fractions containing 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin in the
range of 12.5–100 µg/mL were tested in the viability assays. Readings were performed
using a Biotek Power Wave XS plate spectrophotometer (Biotek® Instruments, Winooski,
VT, USA).
3.5.3. Measurement of Reporter Gene Activity
Measurement of β-galactosidase activity was performed as previously described [34].
Briefly, cells were challenged with an SFE chicory extract with concentrations ranging from
1 µg/mL to the highest nontoxic concentration. For the purified fraction of the SFE extract
containing 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin, the concentrations tested
ranged from 10 ng/mL up to 100 µg/mL. The immunosuppressant drug FK506 (Cayman
Chemicals, Ann Arbor, MI, USA) was used as a positive control at a final concentration of
12.5 µM. The final results were expressed as Miller units (MU) according to the following
equation, where V is the volume of culture assayed in mL, and t is the reaction time in
minutes [44]:
Miller unit = 1000 × (OD420 − 1.75 × OD550)/(t × V × OD600)
3.5.4. Fluorescence Microscopy
The monitoring of Crz1 subcellular localization was performed as previously de-
scribed [34]. Briefly, cells were treated with 7.2 µg/mL of purified fraction of SFE extract
containing the SLs 8-deoxylactucin and its dihydro variant, or12.5 µM of FK506. The
preparations were monitored for GFP fluorescence as previously described using a Zeiss
Imager Z2 (Zeiss, Germany) fluorescence microscope [45]. Photographs were taken with an
Axiocam 506 mono (Zeiss). At least 600 individual cells were counted for each condition.
Images were analyzed using Fiji-ImageJ1.53c (United States).
3.6. Statistical Assays
Results for the toxicity and bioactivity of SFE extract and fraction are the averages of
three independent experiments and are reported as mean ± SD. Differences between the
controls and the experimental concentrations were assessed by an analysis of variance with
Dunnett’s multiple comparison tests (α = 0.05), utilizing GraphPad Prims 8.4.2 software.
The IC50 value for the SFE total extract and the SFE purified fraction was also calculated
using the GraphPad Prims 8.4.2 software.
4. Conclusions
In this study, a green extraction approach using supercritical CO2 was explored for
the first time to recover SLs from Cichorium intybus L. roots. The best operating conditions
to obtain sesquiterpene-rich extracts were achieved at 350 bar and 40 ◦C in a 15 g/min
flow rate (10% EtOH). SFE proved to be an efficient process for extracting SL (53 µg/mg
extract) while reducing the quantity of organic solvents consumed. The SFE method
produced an extract rich in SLs, compounds that had been previously described as anti-
inflammatory in S. cerevisiae model. Moreover, a purified fraction containing a mixture
of noncommercially available 8-deoxylactucin and 11β,13-dihydro-8-deoxylactucin was
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obtained. The SFE extract was then tested for its anti-inflammatory potential, where it
was able to decrease the activity of the calcineurin/NFAT orthologue Crz1 in a S. cerevisiae
model with an IC50 of 38.81 ± 8.32 µg/mL, indicating the possibility of exploiting this
extraction method to produce a possible anti-inflammatory extract using green technology
with reduced costs. The purified fraction’s anti-inflammatory capacity was also measured,
resulting in an inhibition of the pathway with an IC50 of 7.2 ± 3.15 µg/mL, which are
results similar to those of the immunosuppressant pharmaceutical drug FK506. We also
verified the ability of this purified fraction to inhibit the translocation of the transcription
factor Crz1 to the nucleus by cellular localization, observed by fluorescence microscopy.
Calcineurin is highly conserved among eukaryotes, and the docking of the NFAT sequence
recognized by calcineurin is highly similar to Crz1. This makes the yeast model suitable for
studying the interaction of compounds with the mammalian equivalent calcineurin-NFAT
pathway. However, further studies are required in order to validate this anti-inflammatory
potential achieved through the inhibition of NFAT using other advanced mammalian
cellular models and to address the molecular targets of the purified fraction. NFAT nuclear
translocation and target genes expression can confirm the potential previously observed. A
final validation in animal models subjected to an inflammatory insult is ultimately required
for a deeper understanding of the mechanisms, doses, and role of the compounds on
inflammatory biomarkers.
Based on these results, we can consider pressurized fluid extraction technology as a
good alternative to traditional solvent extraction methods for the development of high-
value products from Cichorium intybus L. with potential human health-promoting applica-
tions.
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